EUVIMEDOpdag EUVIMED
Open access

Targeting Melanin Heterogeneity in Metastatic Melanoma: A Dual‐Tumour Mouse Melanoma Model

Marine Delmas iD, Benjamin Chaussin, Nathan Harismendy iD, Aurore Dougé iD, Paul-Olivier Rouzaire iD, Christopher Montemagno iD, Jérôme Durivault iD, Emmanuel Moreau iD, Elisabeth Miot-Noirault iD, Mercedes Quintana iD, Sophie Besse iD, Michel D'Incan iD and 3 more

Experimental Dermatology · 2025

DOI: 10.1111/exd.70159 ↗

At a glance

Journal article in Experimental Dermatology, 2025. Written by Marine Delmas and 14 co-authors. Institution: UMR1240 INSERM, Université Clermont Auvergne, Clermont-Ferrand, France. Major MEDLINE topics: Melanins, Melanoma, Experimental, Skin Neoplasms, Melanoma. Cited 2 times so far (Crossref); 46 references. The full text is freely available in PubMed Central. Funded by: Société Française de Dermatologie et de Pathologie Sexuellement Transmissible, Fondation ARC pour la Recherche sur le Cancer, Ligue Contre le Cancer.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

The combination of melanin‐targeted radionuclide therapy (TRT) and immunotherapy offers potential in overcoming melanoma resistance to conventional therapies. Studying the potential abscopal effect induced by TRT is essential to evaluate such combination. We develop here a preclinical murine model comprising a target (pigmented) and non‐target (non‐pigmented) tumour to study the abscopal effect induced by melanin‐TRT in melanoma. Murine melanoma cell lines were tested: two pigmented (B16‐F10 and B16‐OVA) and one non‐pigmented (B16‐G4F), inoculated in C57BL/6 mice to assess pigmentation levels and immune infiltration. Heterogeneous tumour growth and repigmentation of the B16‐G4F tumour led us to develop a non‐pigmented cell line (B16‐OVAmTYR−/−) by tyrosinase invalidation using CRISPR/Cas9. A dual‐tumour model comprising the B16‐OVA tumour and the B16‐OVAmTYR tumour was evaluated in terms of tumour growth, pigmentation, and immune infiltrate. The B16‐OVA model displayed homogeneous tumour growth, pigmentation and high immune infiltrate (CD8+ T cells p < 0.001; CD4+ T cells p < 0.05, regulatory T cells p < 0.001). The new B16‐OVAmTYR−/− cell line ensured a consistent genetic background for comparative studies. The B16‐OVAmTYR−/− maintained a non‐pigmented phenotype without repigmentation (no melanin expression) and demonstrated similar tumour growth characteristics to its pigmented counterpart (DT = 2.4 ± 0.5 days). Establishing a dual‐tumour model using both B16‐OVA and B16‐OVAmTYR−/− cell lines enabled concurrent study of pigmented and non‐pigmented tumours in a single host, closely mirroring clinical scenarios of metastatic melanoma. We have successfully developed a new dual‐tumour pigmented and non‐pigmented mouse melanoma model mimicking clinical observations to study the abscopal effect in metastatic melanoma.

Subjects

MeSH terms (MEDLINE)

MelaninsMelanoma, ExperimentalSkin NeoplasmsMelanomaAnimalsMiceMice, Inbred C57BLCell Line, TumorDisease Models, AnimalMonophenol MonooxygenaseImmunotherapyPigmentation

Author keywords

abscopal effectimmunotherapymelanomatargeted radionuclide therapy

Substances

MelaninsMonophenol Monooxygenase

Authors and institutions

  • UMR1240 INSERM, Université Clermont Auvergne, Clermont-Ferrand, France.
  • Centre Jean PERRIN, Service de Médecine Nucléaire, Clermont-Ferrand, France.
  • Service d'Oncologie Médicale, CHU Gabriel Montpied, Clermont-Ferrand, France.
  • Laboratoire HLA, CHU Gabriel Montpied, Clermont-Ferrand, France.
  • Département de Biologie Médicale, Centre Scientifique de Monaco, Monaco, France.
  • Service de Dermatologie et d'Oncodermatologie, CHU Estaing, Clermont-Ferrand, France.

ORCID profiles: Marine Delmas, Nathan Harismendy, Aurore Dougé, Paul-Olivier Rouzaire, Christopher Montemagno, Jérôme Durivault, Emmanuel Moreau, Elisabeth Miot-Noirault, Mercedes Quintana, Sophie Besse, Michel D'Incan, Emmanuel Chautard, Elodie Jouberton, Jacques Rouanet

Funding

  • Société Française de Dermatologie et de Pathologie Sexuellement Transmissible
  • Fondation ARC pour la Recherche sur le Cancer
  • Ligue Contre le Cancer

Cite

APA

Delmas, M., Chaussin, B., Harismendy, N., Dougé, A., Rouzaire, P. O., Montemagno, C., Durivault, J., Moreau, E., Miot-Noirault, E., Quintana, M., Besse, S., D'Incan, M., Chautard, E., Jouberton, E., & Rouanet, J. (2025). Targeting Melanin Heterogeneity in Metastatic Melanoma: A Dual‐Tumour Mouse Melanoma Model. Experimental Dermatology. https://doi.org/10.1111/exd.70159

Vancouver

Delmas M, Chaussin B, Harismendy N, Dougé A, Rouzaire PO, Montemagno C, et al. Targeting Melanin Heterogeneity in Metastatic Melanoma: A Dual‐Tumour Mouse Melanoma Model. Experimental Dermatology. 2025. doi:10.1111/exd.70159

BibTeX
@article{Delmas2025,
  author = {Delmas, Marine and Chaussin, Benjamin and Harismendy, Nathan and Dougé, Aurore and Rouzaire, Paul-Olivier and Montemagno, Christopher and Durivault, Jérôme and Moreau, Emmanuel and Miot-Noirault, Elisabeth and Quintana, Mercedes and Besse, Sophie and D'Incan, Michel and Chautard, Emmanuel and Jouberton, Elodie and Rouanet, Jacques},
  title = {Targeting Melanin Heterogeneity in Metastatic Melanoma: A Dual‐Tumour Mouse Melanoma Model},
  journal = {Experimental Dermatology},
  year = {2025},
  doi = {10.1111/exd.70159}
}
Start for free →